Editorial: Real-World Outcomes of Disease-Modifying Therapies Highlight the Need for Diagnostic Biomarkers in Early Alzheimer's Disease
{{output}}
The promise of targeted humanized monoclonal antibody therapies to amyloid ß and tau protein in Alzheimer's disease from clinical trial data has not been realized when put to the test in real-world studies and practice. There have been regulatory approvals f... ...
